Ultrasmall Copper-Based Nanozyme Eye Drops for Effective Antioxidative Therapy of Ocular Surface Diseases

用于有效抗氧化治疗眼表疾病的超小型铜基纳米酶滴眼液

阅读:1

Abstract

Developing an effective strategy to mitigate the excessive production of reactive oxygen species (ROS) caused by diverse factors is crucial for preventing ocular surface diseases. However, due to the inherent characteristics of ocular barriers, the therapeutic efficacy of conventional eye drops remains unsatisfactory. Copper-based nanozymes are known for their enzyme-mimetic ROS scavenging abilities. In this study, we report a simple, ecofriendly, one-step synthesis of ultrasmall copper Cu(5.4)O nanoparticles (NPs) as antioxidant and anti-inflammatory nanozymes in eye drop formulations. The Cu(5.4)O NPs showed strong hydrogen peroxide (H(2)O(2)) scavenging ability and reduced intracellular ROS in corneal cells in vitro. In vitro hemolysis studies and in vivo assessments of ocular biocompatibility confirmed that Cu(5.4)O NP eye drops are safe for application as nanomedicines in ophthalmic formulations. Moreover, in the H(2)O(2)-induced corneal oxidative damage model in mice, Cu(5.4)O NP eye drops effectively scavenged ROS and reduced inflammation, thereby providing protection against oxidative damage and facilitating epithelial regeneration. Collectively, the capabilities of Cu(5.4)O NP-based eye drops offer valuable insights into developing new treatment strategies for ROS-mediated corneal diseases and support the use of nanomaterials in clinical applications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。